Actively Recruiting
Stepwise Strategy for Treatment of Atrialfibrillation Substrate Study
Led by Yuehui Yin · Updated on 2025-08-19
480
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Electrical/pharmacological cardioversion improves structural remodeling of left atrium. We hypothesized that radiofrequency ablation surgery for atrial fibrillation has a higher success rate and a lower recurrence rate of atrial fibrillation in patients with improved atrial stroma. This study is a multicenter, prospective, observational study conducted in China to evaluate whether sacubitril/valsartan can reduce atrial fibrillation recurrence rates, improve cardiac structure and function, and analyze the factors influencing the maintenance rate of sinus rhythm after atrial fibrillation ablation.
CONDITIONS
Official Title
Stepwise Strategy for Treatment of Atrialfibrillation Substrate Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 80 years with persistent atrial fibrillation and left atrial enlargement (40-50mm diameter)
- Willing to undergo atrial fibrillation cardioversion
- Planned to receive amiodarone for pharmacological cardioversion
- Signed written informed consent for participation
- Not participating in other interventional studies concurrently
You will not qualify if you...
- Females who are pregnant, lactating, or planning pregnancy within 2 years
- Arrhythmia not converted to sinus rhythm by medication and refuse electrical cardioversion
- Arrhythmia not convertible to sinus rhythm by medication or electrical cardioversion
- Glomerular filtration rate (eGFR) less than 30 ml/min/1.73m²
- Biliary cirrhosis or cholestasis
- Hyperthyroidism
- History of bradycardia (heart rate less than 50 bpm) or second degree or higher atrioventricular block
- Sick sinus syndrome
- Allergy to iodine, amiodarone, or its excipients
- Use of drugs that prolong QT interval or history of torsades de pointes
- Contraindications to cardioversion, such as cardiac thrombosis or anticoagulation contraindications
- Moderate to severe rheumatic or valvular heart disease; history of atrial-related surgery including valve replacement, ablation, septal defect occlusion, or complex congenital heart surgery
- History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident within 3 months
- NYHA Class III-IV heart failure or ejection fraction less than 40%
- Poor compliance, inability to complete study, or expected lifespan under 1 year
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the second affiliated hospital of CQMU
Chongqing, China
Actively Recruiting
Research Team
Y
Yuehui Yin
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here